Le Lézard
Classified in: Health
Subjects: CCA, ACC

Program for Oncopeptides virtual Capital Markets Day on November 30 is published


STOCKHOLM, Nov. 24, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, today announces that the company has finalized the program for the upcoming virtual capital markets day for investors, analysts and journalists on November 30th, 2020. The program is available on the company's website at: www.oncopeptides.com/en/calendar/

The CMD will be webcasted live and accessible at: https://tv.streamfabriken.com/oncopeptides-cmd-2020.

The presentations from the capital markets day will be uploaded on the company website in conjunction with the meeting.

Oncopeptides Virtual Capital Markets Day
14.00 - 16.00 CET (8:00am-10am EST) November 30th, 2020

"Building a Fully Integrated Biotechnology Company"

Introduction and Strategy for Value Growth - Marty J Duvall, CEO Oncopeptides

Multiple Myeloma

"Myeloma remains one of the largest unmet medical needs within hematology" 

Relapsed refractory multiple myeloma and melflufen - clinical experience with melflufen

Panel discussion

Moderated by Klaas Bakker, MD, PhD, CMO Oncopeptides

The clinical development program for melflufen

"Understanding how melflufen can help patients the most" - Jakob Lindberg, CSO Oncopeptides

Successfully making the drug available for patients in the US

Overview of US launch of melflufen - Marty J Duvall, CEO Oncopeptides

Questions and Answers

For more information, please contact:

Rein Piir, Head of Investor Relations, Oncopeptides
E-mail: [email protected] 
Cell phone: +46 70 853 72 92

The information was submitted for publication at 15.30 CET on November 24, 2020.

About Oncopeptides

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The lead product candidate melflufen, is a first in class peptide-drug conjugate that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Melflufen is in development as a new treatment for the hematological malignancy multiple myeloma and is being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Based on the results from the HORIZON study a New Drug Application has been submitted to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen in combination with dexamethasone for treatment of adult patients with triple-class refractory multiple myeloma. The FDA, has granted the New Drug Application a priority review, with a PDUFA date of February 28, 2021.Oncopeptides' global Headquarters is in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/oncopeptides-ab/r/program-for-oncopeptides-virtual-capital-markets-day-on-november-30-is-published,c3242741

The following files are available for download:

https://mb.cision.com/Main/15404/3242741/1339295.pdf

Press release - Program for Oncopeptides virtual Capital Markets Day

SOURCE Oncopeptides AB


These press releases may also interest you

at 08:35
NanoVibronix, Inc. ("NanoVibronix" or the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has entered into an...

at 08:35
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B...

at 08:35
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial...

at 08:33
Soapy Joe's Car Wash, an award-winning and family-owned car wash operator with 23 locations, today announced April 18, 2024, as the ninth annual Soapy Joe's Day and will celebrate by offering the public free Magic Joe car washes ($20 value) and aims...

at 08:33
Tiger Group is offering for immediate purchase unused packaging and labeling equipment from a shuttered pharmaceutical company. "These useful machines are a great fit for a wide array of industries?not just pharmaceutical and medical but also food...

at 08:31
Dallas Men's Health (DMH), a men's sexual health and aesthetics clinic, proudly introduces new additions to its line of services: ARTAS iXi, an AI-Integrated Robotic Hair Restoration solution. The addition of these capabilities unites the 25 years of...



News published on and distributed by: